Tesamorelin Overview

Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH), designed to stimulate the release of endogenous growth hormone. In preclinical and clinical research, it has been studied for its ability to enhance GH and IGF-1 secretion, regulate metabolic pathways, and support investigations into endocrine signaling.

Falutz J. et al. (2010).

History

Tesamorelin was developed through research into GHRH peptides, building on discoveries that synthetic analogs could prolong the half-life and activity of native GHRH fragments. It was synthesized in the late 1990s and early 2000s as a stabilized peptide with improved pharmacokinetic properties, allowing for sustained GH release in experimental models. Research expanded into its effects on metabolic regulation and endocrine function, where it has remained an important tool in laboratory and clinical studies.

Gertner J.M. et al. (2002).

Tesamorelin Structure

CAS #: 218949-48-5

Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S

Molecular Weight: ~5135.9 g/mol

PubChem ID: 16132314

Research Findings

Tesamorelin has been studied in endocrine, metabolic, and molecular models, with research highlighting its activity in growth hormone release, IGF-1 signaling, metabolism, and protein synthesis pathways. Studies also report effects on lipid and glucose metabolism, insulin sensitivity, and cellular proliferation in preclinical systems.

Key Areas of Research:

• Endocrine: GH, IGF-1, metabolism

• Metabolic: lipid, glucose, insulin sensitivity

• Cellular: proliferation, repair, protein synthesis

Together, these findings suggest broad experimental potential for Tesamorelin across endocrine, metabolic, and cellular pathways. By modulating GH and IGF-1 signaling and influencing metabolic and protein synthesis processes, Tesamorelin provides a versatile research platform for exploring tissue repair, metabolic regulation, and growth biology in laboratory models.

Falutz J. et al., 2010

References

Falutz J. et al. (2010). Effects of Tesamorelin, a GHRH analog, on visceral fat in research studies. N Engl J Med, 362(6): 520–531.

Allas S. et al. (2011). Metabolic effects of Tesamorelin in research populations. J Clin Endocrinol Metab, 96(1): 13–22.

Gertner J.M. et al. (2002). Pharmacokinetics and endocrine effects of Tesamorelin, a stabilized GHRH analog. J Clin Endocrinol Metab, 87(10): 4727–4733.